Entering text into the input field will update the search result below

J&J's Janssen wins arbitration versus Genmab over royalty payments for Darzalex

Apr. 08, 2022 6:13 AM ETGenmab A/S (GMAB) Stock, JNJ StockHALO, GNMSFBy: Ravikash Bakolia, SA News Editor

Genmab (GMAB) said an arbitral tribunal has ruled in favor of Johnson & Johnson's (NYSE:JNJ) Janssen Biotech in both matters related to royalty payments under their license agreement related to cancer drug daratumumab.

On the first issue, the tribunal determined by majority opinion that Janssen’s

Recommended For You

More Trending News

Related Stocks

SymbolLast Price% Chg
JNJ
--
GMAB
--